Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Classical hematology 3

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 35Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 26Multiple Myeloma 24Leukemia, Myeloid, Acute 21Recurrence 19Neoplasm Metastasis 17Colorectal Neoplasms 17Ovarian Neoplasms 15Lymphoma, Non-Hodgkin 15Carcinoma, Renal Cell 15Melanoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Follicular 12Urinary Bladder Neoplasms 11Myelodysplastic Syndromes 11Lung Neoplasms 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Hematologic Neoplasms 10Carcinoma, Hepatocellular 10Stomach Neoplasms 9Prostatic Neoplasms 9Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Adenocarcinoma 9Thyroid Neoplasms 8

Interventions

voxelotor 1maltodextrin 1Glutamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has announcements × Anemia, Sickle Cell × Clear all
NCT03036813 2023-07-27

GBT_HOPE

Pfizer

Phase 3 Completed
449 enrolled 17 charts 1 FDA
Classical hematology

Anemia, Sickle Cell

NCT01179217 2020-08-19

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Emmaus Medical, Inc.

Phase 3 Completed
230 enrolled 19 charts 1 FDA
Classical hematology

Vaso-Occlusive Crises, Anemia, Sickle Cell

NCT01895361 2020-01-31

SUSTAIN

Reprixys Pharmaceutical Corporation

Phase 2 Completed
198 enrolled 18 charts 1 FDA
Classical hematology

Anemia, Sickle Cell, Priapism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡